{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-TNF&page=3", "query": { "intervention": "Anti-TNF", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 183, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-TNF&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-TNF&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T17:23:14.140Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00106522", "title": "A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "tocilizumab [RoActemra/Actemra]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 499, "start_date": "2005-05", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-11-12T17:23:14.140Z", "location_count": 97, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 81 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00106522" }, { "nct_id": "NCT03652961", "title": "Rheumatoid Arthritis Memory B Cells and Abatacept", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "DMARDs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2019-06-02", "completion_date": "2021-09-27", "has_results": true, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-11-12T17:23:14.140Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT03652961" }, { "nct_id": "NCT01298492", "title": "A Study To Monitor Long-Term Treatment With PF-00547659", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "PF-00547659", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 268, "start_date": "2011-07-01", "completion_date": "2016-07-27", "has_results": true, "last_update_posted_date": "2021-06-03", "last_synced_at": "2026-11-12T17:23:14.140Z", "location_count": 47, "location_summary": "La Jolla, California • Orange, California • Lafayette, Colorado + 21 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Lafayette", "state": "Colorado" }, { "city": "Thornton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01298492" }, { "nct_id": "NCT01526057", "title": "A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "PF-05280586", "type": "BIOLOGICAL" }, { "name": "MabThera", "type": "BIOLOGICAL" }, { "name": "Rituxan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2012-03-20", "completion_date": "2014-05-07", "has_results": true, "last_update_posted_date": "2019-11-19", "last_synced_at": "2026-11-12T17:23:14.140Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01526057" }, { "nct_id": "NCT02552212", "title": "Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Axial Spondyloarthritis", "Nonradiographic Axial Spondyloarthritis", "Nr-axSpA" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB BIOSCIENCES GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2015-09", "completion_date": "2020-05", "has_results": true, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-11-12T17:23:14.140Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02552212" }, { "nct_id": "NCT04529902", "title": "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - TNFi vs Abatacept", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Tumor Necrosis Factor Inhibitors", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63013, "start_date": "2020-08-17", "completion_date": "2021-08-31", "has_results": false, "last_update_posted_date": "2021-11-23", "last_synced_at": "2026-11-12T17:23:14.140Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04529902" }, { "nct_id": "NCT00049751", "title": "Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3000, "start_date": "2002-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-08-15", "last_synced_at": "2026-11-12T17:23:14.140Z", "location_count": 54, "location_summary": "Mobile, Alabama • Apple Valley, California • Bakersfield, California + 50 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Apple Valley", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Napa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049751" }, { "nct_id": "NCT03512275", "title": "A Study of Bermekimab in Patients With Hidradenitis Suppurativa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "Bermekimab Monoclonal Antibody 400 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2018-06-20", "completion_date": "2019-01-14", "has_results": true, "last_update_posted_date": "2022-03-14", "last_synced_at": "2026-11-12T17:23:14.140Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03512275" }, { "nct_id": "NCT00771667", "title": "A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Placebo (IP)", "type": "DRUG" }, { "name": "Ustekinumab 1mg/kg (IP)", "type": "DRUG" }, { "name": "Ustekinumab 3 mg/kg (IP)", "type": "DRUG" }, { "name": "Ustekinumab 6 mg/kg (IP)", "type": "DRUG" }, { "name": "Placebo IV - Responder - Placebo SC (MP)", "type": "DRUG" }, { "name": "Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)", "type": "DRUG" }, { "name": "Ustekinumab IV - Responder - Placebo SC (MP)", "type": "DRUG" }, { "name": "Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)", "type": "DRUG" }, { "name": "Ustekinumab IV - Nonresponder - Placebo SC (MP)", "type": "DRUG" }, { "name": "Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centocor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 526, "start_date": "2008-12", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2013-04-01", "last_synced_at": "2026-11-12T17:23:14.140Z", "location_count": 88, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • La Jolla, California + 85 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Roseville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00771667" }, { "nct_id": "NCT01793519", "title": "Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 290, "start_date": "2013-01", "completion_date": "2024-08-30", "has_results": false, "last_update_posted_date": "2024-02-28", "last_synced_at": "2026-11-12T17:23:14.140Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01793519" } ] }